Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma

We evaluated the usefulness of the 2017 definition of borderline pancreatic ductal adenocarcinoma (BR-PDAC) in fit patients (performance status 0–1) based on anatomical (A) and biological dimensions (B). From 2011 to 2018, 139 resected patients with BR-PDAC according to the 2017 definition were incl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2020-03, Vol.20 (2), p.223-228
Hauptverfasser:	Medrano, J., Garnier, J., Ewald, J., Marchese, U., Gilabert, M., Launay, S., Poizat, F., Giovannini, M., Delpero, J.R., Turrini, O.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Borderline Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - surgery Chemotherapy Classification Consensus Female Fluorouracil - therapeutic use Folfirinox Humans Irinotecan - therapeutic use Leucovorin - therapeutic use Lymph nodes Lymphatic Metastasis Lymphatic system Male Metastases Metastasis Middle Aged Mortality Multivariate analysis Neoplasm Staging Oxaliplatin - therapeutic use Pancreas Pancreatectomy Pancreatic adenocarcinoma Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - surgery Patients Reference Standards Surgery Survival Survival Analysis Treatment Outcome Veins & arteries
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We evaluated the usefulness of the 2017 definition of borderline pancreatic ductal adenocarcinoma (BR-PDAC) in fit patients (performance status 0–1) based on anatomical (A) and biological dimensions (B). From 2011 to 2018, 139 resected patients with BR-PDAC according to the 2017 definition were included: 18 patients underwent upfront pancreatectomy (CA 19-9 > 500 U/mL and/or regional lymph node metastasis; BR-B group), and 121 received FOLFIRINOX (FX) induction chemotherapy and were divided into BR-A (CA 19-9 500 U/mL and/or regional lymph node metastasis; n = 53) groups. The 3 groups were comparable according to patient characteristics (except for back pain (P
ISSN:	1424-3903 1424-3911
DOI:	10.1016/j.pan.2019.12.001